**Name of journal:** *World Journal of Pharmacology*

**ESPS Manuscript NO: 4025**

**Columns: REVIEW**

**Roles of cholinergic receptors during attentional modulation of cue detection**

**Burk JA***.* Muscarinic and nicotinic receptors

Joshua A Burk

**Joshua A Burk,** Department of Psychology, College of William and Mary, Williamsburg, VA 23187, United States

**Author contributions:** Burk JA solely contributed to this paper.

**Supported by** AG030646 and the Jeffress Memorial Trust

**Correspondence to: Joshua A Burk**, **Associate Professor,** Department of Psychology,College of William and Mary, 540 Landrum Drive PO Box 8795 Williamsburg, VA 23187, United States.jabur2@wm.edu

**Telephone:** +1**-**757-2213882 **Fax:** +1-757-2213896

**Received:** June 9, 2013 **Revised:** August 17, 2013

**Accepted:** September 13, 2013

**Published online:**

**Abstract**

Basal forebrain corticopetal cholinergic neurons are known to be necessary for normal attentional processing. Alterations of cholinergic system functioning have been associated with several neuropsychiatric diseases, such as Alzheimer’s disease and schizophrenia, in which attentional dysfunction is thought to be a key contributing factor. Loss of cortical cholinergic inputs impairs performance in attention-demanding tasks. Moreover, measures of acetylcholine with microdialysis and, more recently, of choline with enzyme-coated microelectrodes have begun to elucidate the precise cognitive demands that activate the cholinergic system on distinct time scales. However, the receptor actions following acetylcholine release under attentionally-challenging conditions are only beginning to be understood. The present review is designed to summarize the evidence regarding the actions of acetylcholine at muscarinic and nicotinic receptors under cognitively challenging conditions in order to evaluate the functions mediated by these two different cholinergic receptor classes. Moreover, evidence that supports beneficial effects of muscarinic muscarinic-1 receptor agonists and selective nicotinic receptor subtype agonists for cognitive processing will be discussed. Finally, some challenges and limitations of targeting the cholinergic system for treating cognitive deficits along with future research directions will be mentioned. In conclusion, multiple aspects of cholinergic neurotransmission must be considered when attempting to restore function of this neuromodulatory system.

© 2013 Baishideng. All rights reserved.

**Key words:** 192 IgG-saporin; Acetylcholinesterase inhibitors; Alzheimer’s disease; Attention; Basal forebrain; Muscarinic; Nicotinic; Protein kinase C; Prefrontal cortex; Schizophrenia

**Core tip:** The corticopetal cholinergic system is critical for normal attentional processing. Disruption of this system is associated with cognitive deficits in several disorders. Thus, restoration of cortical cholinergic neurotransmission represents a reasonable target for treating some cognitive disorders. Evidence is presented that the muscarinic muscarinic-1 receptor and nicotinic receptor subtypes appear to be key targets for future investigations related to treating cognitive disorders. Future research into muscarinic-nicotinic receptor interactions, along with the role of second messenger systems, is needed to further develop appropriate strategies for restoring cortical cholinergic neurotransmission.

Burk JA. Roles of cholinergic receptors during attentional modulation of cue detection

**Available from:**

**DOI:**

**INTRODUCTION**

Cortically-projecting cholinergic neurons originate from the nucleus basalis of Meynert and substantia innominata within the basal forebrain[1]. Numerous hypotheses have been put forth proposing that the cortical cholinergic system is critical for the selection and subsequent processing of stimuli[2,3]. Several other theories have proposed roles for cortical cholinergic inputs in learning and memory[4,5], but the focus of this mini-review will be with regard to the contribution of these pathways to attention. Several cortical regions, including prefrontal cortex, posterior parietal cortex and some somatosensory cortical areas[6], are thought to be sites where acetylcholine can modulate neural activity to impact aspects of attentional processing[2,7,8]. The evidence in support of these hypotheses has come from multiple experimental approaches.

In rats, intrabasalis infusions of excitotoxic compounds that preferentially destroyed cholinergic neurons tended to produce larger deficits in tasks that placed greater demands on attentional processing[9,10]. The immunotoxin, 192 IgG-saporin, which destroys cortically-projecting basal forebrain cholinergic neurons, has been an important tool for studying the impact of loss of the cholinergic system on attention[11]. Intrabasalis infusions of 192 IgG-saporin decrease signal detection accuracy in attention-demanding tasks[12-14]. Measures of acetylcholine using microdialysis techniques have found elevations in acetylcholine associated with attention-demanding tasks compared with procedures that control for motoric or motivational aspects of performance[15-17]. More recently, enzyme-coated microelectrodes have been used to measure choline and acetylcholine release on a much shorter time scale[18,19]. Experiments employing these techniques have shown that there are cholinergic transients on different timescales during cue detection tasks[20,21]. Moreover, these transients tend to occur during a transition from a trial when no signal is perceived to a trial when a signal is detected and the appropriate response rules are then activated[22]. Thus, the previous evidence has supported the idea that cortical acetylcholine contributes importantly to aspects of cue detection and variations in cognitive demands. Despite these important findings, the most effective pharmacological strategies to activate cholinergic neurons to restore normal functioning remain unclear. The goal of the present minireview is to summarize some key findings regarding the activation of muscarinic and nicotinic receptors during cue detection and to suggest future research areas that may facilitate the development of drug treatments aimed at restoring normal cholinergic neurotransmission.

**ACETYLCHOLINE AND ALZHEIMER’S DISEASE: CURRENT CHOLINERGIC DRUG TREATMENTS**

Alzheimer’s disease is characterized, in early stages, by deficits in attentional[23,24] and mnemonic processing[4]. Loss of cholinergic neurons in the basal forebrain has been implicated in the cognitive deficits associated with Alzheimer’s disease[4,25]. A wide variety of neuropathological changes have been noted in Alzheimer’s disease, with the major features including the development of β-amyloid-induced plaques and neurofibrillary tangles, although the exact contribution of these features to disease progression has remained controversial[26,27].

Interestingly, alterations of cholinergic functioning appear to interact with many of the key neuropathological changes in Alzheimer’s disease[28]. For example, elevated levels of amyloid-β42 suppresses acetylcholine synthesis[29,30]. Immunotoxic lesions of cholinergic neurons alter amyloid precursor protein secretion[31]. In animal models, loss of muscarinic-1 (M1) receptor stimulation exacerbates the development of plaques and tangles[32]. Conversely, muscarinic M1/M3 receptor stimulation decreases amyloid-β42 levels[33]. Similarly, recent reports have shown that α7 nicotinic receptor agonists can also decrease amyloid-β42 levels[34,35]. Thus, the available evidence suggests, broadly, that there is a negative correlation between neuropathological features leading to plaques and activity of the cholinergic system. Thus, it is possible that restoration of optimal cholinergic functioning could assist in improving other aspects of Alzheimer’s disease. The relationship between the cholinergic system and tangles is less well-characterized. In patients with Alzheimer’s disease, choline acetyltranferase-positive basal forebrain neurons do show tau pathology[36]. Elevated levels of tau can be neurotoxic to M1/M3-containing neurons, an effect thought to be related to the high affinity of tau for these receptors[37]. Activation of M1 receptors appears to lessen tau pathology, while nicotinic receptor stimulation can exacerbate tau pathology[38]. Thus, although cholinergic restoration may be beneficial, approaches that provide more modest levels of cholinergic stimulation may limit adverse effects.

Given the loss of cholinergic functioning in Alzheimer’s disease, it is not surprising that restoring these pathways has received considerable attention to treat the cognitive deficits. Drugs that inhibit acetylcholinesterase (AChE), the enzyme that deactivates acetylcholine, have been used to treat Alzheimer’s disease. The original approved AChE inhibitor approved for treatment of Alzheimer’s disease, tacrine, was associated with a relatively high incidence of side effects, including hepatotoxicity[39]. The newer generation of AChE inihibitors, donepezil, galantamine, and rivastigmine, provide modest beneficial effects with a lower rate and severity of side effects compared with tacrine[40]. Additionally, a n-methyl-*D*-aspartate (NMDA) receptor antagonist, memantine, has been approved and appears to have beneficial effects when administered later in the progression of Alzheimer’s disease[41]. The limited beneficial effects of the AChE inhibitors may be due to the widespread action these compounds have on multiple cholinergic receptors. A focus on more specific actions at certain cholinergic receptor subtypes may yield improved treatments for the cognitive deficits in Alzheimer’s disease. Additionally, efforts to facilitate the action of acetylcholine binding, such as through allosteric receptor agonists or compounds that sensitize specific cholinergic receptors, may be beneficial.

**MUSCARINIC RECEPTORS**

Five muscarinic receptor subtypes have been characterized, M1-M5[42]. The M1, M3 and M5 receptors are primarily coupled to Gq proteins and can upregulate phospholipase C and activate inositol triphosphate, which can inhibit potassium currents[43]. The M2 and M4 receptors are coupled to Gi or Go proteins, typically having inhibitory effects. The M1 and M2 receptors have been most carefully studied with respect to cognition. Generally, the M1 receptors are located postsynaptically whereas the M2 receptors are most predominantly located in presynaptically, serving as autoreceptors to inhibit acetylcholine release[44]. Many experiments have demonstrated that M1 receptor blockade can impair aspects of learning and memory[45-49]. With regard to attention, a muscarinic M1 antagonist did not affect performance in a task that required a simultaneous discrimination when visual stimuli were presented in one of two locations[50]. However, in a successive visual discrimination, when a visual stimulus is presented (or not) from a single location, M1 receptor blockade did decrease performance and this decrease in performance was seen at lower doses when a visual distracter was presented[51]. Thus, the M1 receptor system may not be essential when explicit attentional demands are minimal, but may be more likely to be recruited as task demands increase, such as in a successive discrimination task[52] . These findings are consistent with other results indicating that loss of cortical cholinergic inputs does not yield deficits following manipulations of any single attentional task parameter, but impairments are observed when multiple parameters are adjusted to increase explicit attentional demands[53]. Electrophysiological experiments have provided further evidence about neural processes that are supported by muscarinic M1 receptors. For example, muscarinic M1 receptors are sufficient for acetylcholine-induced prolonged cortical pyramidal cell excitability and at least partially contribute to transient inhibitory and excitatory activity in different cortical neurons[54]. Moreover, M1 receptor deficient mice show less of a shift toward a frequency coupled with stimulation of the basal forebrain, suggesting that the muscarinic M1 receptor is important for auditory cortical experience dependent plasticity[55]. Collectively, the data provide strong support that modulation of the muscarinic M1 receptor critically contributes to several processes that are important for normal learning.

Muscarinic M2 receptor antagonists enhance performance in several measures of working memory, including in radial arm maze win-shift and win-stay tasks and delayed nonmatching to position tasks[46,56]. Moreover, M2 receptor antagonists can enhance memory in aged animals[57]. Not surprisingly, M2 receptor antagonists increase acetylcholine release[57,58], although it is unknown whether this is mechanism underlying enhanced memory performance following muscarinic M2 receptor blockade. Blockade of muscarinic M2 receptors has also been shown to enhance long-term potentiation, which may contribute to the reported cognitive benefits of drugs that act in this manner[59]. The effects of muscarinic M2 receptor antagonist administration on measures of attention have not been examined. Thus, the extent to which attentional enhancement may contribute to the memory improvement following muscarinic M2 receptor blockade remains unclear.

There is growing evidence that other muscarinic receptor subtypes contribute to aspects of cognition. For example, muscarinic M3 receptor knockout mice display deficits in contextual fear conditioning[60]. The development of more selective muscarinic toxins should greatly enhance the ability to study the roles of specific muscarinic receptor subtypes. These toxins have been used to show that inhibition of muscarinic M1 receptors, but not M4 receptors, in the dorsomedial striatum disrupts place reversal learning[48].

**NICOTINIC RECEPTORS**

When acetycholine binds to nicotinic receptors, release of several neurotransmitters is promoted and several processes are activated, including elevation of intracellular calcium levels[61-63]. There are two predominant neuronal nicotinic receptor subtypes, those containing α4β2 subunits and those containing the α7 subunit. The α4β2 subtype has a higher affinity for nicotine compared with the α7 subtype[64]. The available evidence suggests that α7- and α4β2-subunit containing receptors are located pre- and postsynaptically in the brain, with a larger proportion of these receptors located presynaptically[65,66].

Many experiments have examined the role of nicotinic receptors in attention. There appears to be sharp age-related differences in the effects of nicotine exposure on cognition. In rodents, prenatal nicotine exposure produces attentional impairments[41]. Adolescent nicotine exposure impairs attention[67,68] and learning[69,70]. In adults, acute nicotine exposure can have beneficial effects, although nicotine-induced performance improvement is occasionally observed during specific task conditions[71,72]. Moreover, impairments in attentional performance have been reported following nicotinic receptor blockade, however, changes in variables thought to reflect nonspecific aspects of performance have complicated the interpretation of these data[73,74]. Chronic nicotine exposure, on the other hand, appears to robustly enhance performance in attention-demanding tasks in rats[75], similar to findings in human smokers[76].

The exact mechanisms of nicotine-induced attentional enhancement in adults are beginning to become better understood. A recently published experiment failed to find effects of nicotine or a selective nicotinic α4β2 receptor agonist, S 38232, on a well-trained attention task. However, when attentional demands were increased, the α4β2 receptor agonist, but not nicotine, enhanced attentional performance[77]. Examination of putative cholinergic transients in the prefrontal cortex found that the α4β2 receptor agonist produced a faster rise time and steeper decay compared with nicotine[77]. Subsequent experiments showed that nicotine and blockade of α7 nicotinic receptors also enhanced performance, suggesting that the actions of nicotine at α7 nicotinic receptors may slow the rise time and decay of cholinergic transients, which may be a critical factor for enhancement of attentional performance under taxing conditions[77]. Recent data have supported the idea that agents, such as sazetidine-A, which desensitize α4β2 nicotinic receptors, can enhance attentional performance and reverse deficits induced by blockade of NMDA or muscarinic receptors[78,79]. Thus, the available data provide strong evidence that α4β2 nicotinic receptors are important targets for regulating attentional performance.

Several studies have begun to examine the role of nicotinic α7 receptor agonists in attention[80]. Nicotinic α7 nicotinic receptor knock-out mice are not different from controls during baseline performance of the five-choice serial reaction time task, but do demonstrate elevated omissions when task demands are increased[81]. Moreover, α7 nicotinic receptor agonists facilitate aspects of pre-attentive processing[82,83]. However, α4β2 receptor agonists, but not α7 agonists, can reverse vigilance decrements in the five choice serial reaction time task[84]. Thus, there is evidence that nicotinic α7 receptor agonists can facilitate attention, although additional work is needed to clarify the aspects and conditions under which attentional processing can be enhanced by these compounds.

**INTERACTIONS BETWEEN MUSCARINIC AND NICOTINIC RECEPTORS: PHARMACOLOGICAL EVIDENCE**

Administration of cholinergic receptor-specific drugs has been used to study the relationship between muscarinic and nicotinic receptors. Several experiments have demonstrated that co-administration of muscarinic and nicotinic receptor antagonists, at doses that do not have effects when either receptor is blocked alone, can disrupt performance in attention- and memory-demanding tasks[73,85,86]. Moreover, as mentioned above, attentional impairments following blockade of muscarinic receptors can be overcome by drugs that desensitize α4β2 nicotinic receptors[79]. The ability of muscarinic, particularly M1 receptor agonists, to restore attentional processing following nicotinic receptor blockade has not been well-characterized. Collectively, the available evidence suggests that decreasing cholinergic receptor activity at multiple subtypes can have a synergistic negative effect on attentional performance and that agonism, increasing the activity of α4β2 nicotinic receptors, can overcome attentional deficits following muscarinic receptor blockade. Notably, reversing the effects of muscarinic receptor blockade on attentional processing is not exclusively accomplished by α4β2 nicotinic receptor agonists[87]. Nicotinic receptor agonists can also reverse scopolamine-induced deficits in measures of memory[88], although the focus of this minireview is primarily on attentional processing.

**FUTURE RESEARCH DIRECTIONS: RESTORING CHOLINERGIC NEUROTRANSMISSION**

***Modes of cholinergic neurotransmission***

Actions at cholinergic receptors have traditionally thought to reflect “volume” transmission, reflecting sensitivity to acetylcholine levels beyond the synapse. Part of the evidence in support of this idea is the location of cholinergic receptors, with nicotinic receptors predominantly located presynaptically and relatively few cholinergic varicosities forming classical synapses onto muscarinic M1 receptors in cortical pyramidal cells[89]. However, the use of choline-sensitive microelectrodes has provided evidence that phasic acetylcholine release, over several seconds, can predict aspects of trial-by-trial attentional performance[20,22,90]. Thus, there is developing evidence that acetylcholine may act on multiple time scales[21]. The functional implications of these different modes of transmission are not well-understood. Given these findings, treatments that maintain or facilitate cholinergic transmission modes by binding to allosteric sites on cholinergic receptors may be beneficial.

Allosteric agonists considerable potential for treating cognitive deficits associated with cholinergic dysfunction. Several of these compounds have been thoroughly discussed in other reviews[91-93] so only a few allosteric ligands will be highlighted in this minireview to illustrate the progress and challenges with this approach. One compound in clinical trials for treating Alzheimer’s disease and schizophrenia is the nicotinic α7 receptor-sensitizing agent, EVP-6124. This compound can enhance mnemonic processing, though its effects on attention remain less clear[94]. Although the precise mechanism of action of EVP-6124 is unclear, it is hypothesized that at least two pockets within the channel must be bound to activate the α7 receptor and that low doses of EVP-6124 can fill a small portion of the sites, allowing the same level of endogenous acetylcholine to activate more α7 nicotinic receptors[94]. Another compound that has been shown to have beneficial effects in rodent models of attentional dysfunction is the α4β2 agent, sazetidine-A[78]. Curiously, this compound initially stimulates and then desensitizes alpha4beta2 receptors. Additional studies of the impact of this drug on acetylcholine and glutamate release may yield further insights into the exact mechanisms through which sazetidine-A can reverse attentional deficits. With regard to positive allosteric modulators of muscarinic receptors, challenges have existed with developing sufficiently targeted compounds[91], although more recent reports provide encouraging progress[95]. Overall, the positive results observed with initial allosteric agonists, along with novel insights about cholinergic transmission modes and potential disease-modifying effects of restoring cholinergic transmission, all lend support to the importance of further research with cholinergic receptor positive allosteric modulators.

***Contributions of second messenger systems to attentional processing***

As mentioned above, activation of both muscarinic and nicotinic receptors can induce further intracellular signaling cascades. The role of second messenger systems in attentional processing remains poorly understood. These systems may contribute to activation of response rules following cue detection or engagement of top-down mechanisms that guide attention. For example, inhibition of protein kinase A in the prefrontal cortex impairs attentional performance[96]. Protein kinase C (PKC) is activated by muscarinic M1 receptors and is lower in patients with Alzheimer’s disease[101-103]. Moreover, as Alzheimer’s disease progresses, there is increased M1 receptor/G-protein decoupling, suggesting that drugs targeting the muscarinic M1 receptor may only be effective in early disease stages[100]. Furthermore, this M1 receptor/G-protein decoupling correlates with the loss of PKC activity in Alzheimer’s disease[100]. PKC inhibition impairs signal detection in attention-demanding tasks in rats, a finding consistent with the idea that lower PKC activity may contribute to attentional deficits during early stages of Alzheimer’s disease[51]. These findings support the idea that PKC activators may be beneficial for Alzheimer’s disease[101,102]. These preliminary experiments suggest that a focus on the role of second messenger systems is likely to provide insight into modulation of attentional processing and may offer useful targets for treating some cognitive disorders.

**CONCLUSION**

The muscarinic and nicotinic receptor systems are well-known to contribute to cognitive processing and to be disrupted in diseases characterized by cognitive deficits. Surprisingly, there are relatively few studies that examine combined agonism of muscarinic M1 receptor and nicotinic receptor subtypes in treating attentional deficits. The benefits derived from this approach will likely be determined, at least in part, by the ability to normalize cholinergic neurotransmission on multiple time scales. Allosteric agonists may be beneficial for achieving this goal. It will also be important to maintain the effects of cholinergic signaling on downstream signaling, such as PKC activation. Collectively, these approaches may yield greater benefits for cognitive disorders associated with corticopetal cholinergic dysfunction.

**REFERENCES**

1 **Mesulam MM**, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). *Neuroscience* 1983; **10**: 1185-1201 [PMID: 6320048 DOI: 10.1016/0306-4522(83)90108-2]

2 **Everitt BJ**, Robbins TW. Central cholinergic systems and cognition. *Annu Rev Psychol* 1997; **48**: 649-684 [PMID: 9046571 DOI: 10.1146/annurev.psych.48.1.649]

3 **Sarter M**, Givens B, Bruno JP. The cognitive neuroscience of sustained attention: where top-down meets bottom-up. *Brain Res Brain Res Rev* 2001; **35**: 146-160 [PMID: 11336780 DOI: 10.1016/S0165-0173(01)00044-3]

4 **Bartus RT**, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science* 1982; **217**: 408-414 [PMID: 7046051 DOI: 10.1126/science.7046051]

5 **Drachman DA**. Memory and cognitive function in man: does the cholinergic system have a specific role? *Neurology* 1977; **27**: 783-790 [PMID: 560649 DOI: 10.1212/WNL.27.8.783]

6 **Klinkenberg I**, Sambeth A, Blokland A. Acetylcholine and attention. *Behav Brain Res* 2011; **221**: 430-442 [PMID: 21108972 DOI: 10.1016/j.bbr.2010.11.033]

7 **Petersen SE**, Posner MI. The attention system of the human brain: 20 years after. *Annu Rev Neurosci* 2012; **35**: 73-89 [PMID: 22524787 DOI: 10.1146/annurev-neuro-062111-150525]

8 **Sarter M**, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. *Brain Res Brain Res Rev* 2005; **48**: 98-111 [PMID: 15708630 DOI: 10.1016/j.brainresrev.2004.08.006]

9 **Muir JL**, Everitt BJ, Robbins TW. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. *J Neurosci* 1994; **14**: 2313-2326 [PMID: 7512637]

10 **Robbins TW**, Everitt BJ, Marston HM, Wilkinson J, Jones GH, Page KJ. Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. *Behav Brain Res* 1989; **35**: 221-240 [PMID: 2688683 DOI: 10.1016/S0166-4328(89)80143-3]

11 **McGaughy J**, Everitt BJ, Robbins TW, Sarter M. The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. *Behav Brain Res* 2000; **115**: 251-263 [PMID: 11000424 DOI: 10.1016/S0166-4328(00)00262-X]

12 **Dalley JW**, Theobald DE, Bouger P, Chudasama Y, Cardinal RN, Robbins TW. Cortical cholinergic function and deficits in visual attentional performance in rats following 192 IgG-saporin-induced lesions of the medial prefrontal cortex. *Cereb Cortex* 2004; **14**: 922-932 [PMID: 15084496 DOI: 10.1093/cercor/bhh052]

13 **McGaughy J**, Kaiser T, Sarter M. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. *Behav Neurosci* 1996; **110**: 247-265 [PMID: 8731052 DOI: 10.1037/0735-7044.110.2.247]

14 **McGaughy J**, Dalley JW, Morrison CH, Everitt BJ, Robbins TW. Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. *J Neurosci* 2002; **22**: 1905-1913 [PMID: 11880520]

15 **Arnold HM**, Burk JA, Hodgson EM, Sarter M, Bruno JP. Differential cortical acetylcholine release in rats performing a sustained attention task versus behavioral control tasks that do not explicitly tax attention. *Neuroscience* 2002; **114**: 451-460 [PMID: 12204214 DOI: 10.1016/S0306-4522(02)00292-0]

16 **Himmelheber AM**, Sarter M, Bruno JP. Increases in cortical acetylcholine release during sustained attention performance in rats. *Brain Res Cogn Brain Res* 2000; **9**: 313-325 [PMID: 10808142 DOI: 10.1016/S0926-6410(00)00012-4]

17 **Passetti F**, Dalley JW, O'Connell MT, Everitt BJ, Robbins TW. Increased acetylcholine release in the rat medial prefrontal cortex during performance of a visual attentional task. *Eur J Neurosci* 2000; **12**: 3051-3058 [PMID: 10971646 DOI: 10.1046/j.1460-9568.2000.00183.x]

18 **Burmeister JJ**, Pomerleau F, Huettl P, Gash CR, Werner CE, Bruno JP, Gerhardt GA. Ceramic-based multisite microelectrode arrays for simultaneous measures of choline and acetylcholine in CNS. *Biosens Bioelectron* 2008; **23**: 1382-1389 [PMID: 18243683 DOI: 10.1016/j.bios.2007.12.013]

19 **Parikh V**, Apparsundaram S, Kozak R, Richards JB, Sarter M. Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice. *Neuroscience* 2006; **141**: 379-389 [PMID: 16675138 DOI: 10.1016/j.neuroscience.2006.03.055]

20 **Parikh V**, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. *Neuron* 2007; **56**: 141-154 [PMID: 17920021 DOI: 10.1016/j.neuron.2007.08.025]

21 **Parikh V**, Sarter M. Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity. *Ann N Y Acad Sci* 2008; **1129**: 225-235 [PMID: 18591483 DOI: 10.1196/annals.1417.021]

22 **Howe WM**, Berry AS, Francois J, Gilmour G, Carp JM, Tricklebank M, Lustig C, Sarter M. Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. *J Neurosci* 2013; **33**: 8742-8752 [PMID: 23678117 DOI: 10.1523/JNEUROSCI.5809-12.2013]

23 **Berardi AM**, Parasuraman R, Haxby JV. Sustained attention in mild Alzheimer's disease. *Dev Neuropsychol* 2005; **28**: 507-537 [PMID: 15992254 DOI: 10.1207/s15326942dn2801\_4]

24 **Parasuraman R**, Greenwood PM, Alexander GE. Selective impairment of spatial attention during visual search in Alzheimer's disease. *Neuroreport* 1995; **6**: 1861-1864 [PMID: 8547585 DOI: 10.1097/00001756-199510020-00010]

25 **Whitehouse PJ**, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. *Science* 1982; **215**: 1237-1239 [PMID: 7058341 DOI: 10.1126/science.7058341]

26 **Castellani RJ**, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. *Arch Med Res* 2012; **43**: 694-698 [PMID: 23085451 DOI: 10.1016/j.arcmed.2012.09.009]

27 **Wisniewski HM**, Wegiel J. Alzheimer's disease neuropathology. Current status of interpretation of lesion development. *Ann N Y Acad Sci* 1992; **673**: 270-284 [PMID: 1485725 DOI: 10.1111/j.1749-6632.1992.tb27463.x]

28 **Schliebs R**, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. *J Neural Transm* 2006; **113**: 1625-1644 [PMID: 17039298 DOI: 10.1007/s00702-006-0579-2]

29 **Hoshi M**, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K, Hoshino T, Imahori K. Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. *J Biol Chem* 1997; **272**: 2038-2041 [PMID: 8999897 DOI: 10.1074/jbc.272.4.2038]

30 **Pedersen WA**, Kloczewiak MA, Blusztajn JK. Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. *Proc Natl Acad Sci U S A* 1996; **93**: 8068-8071 [PMID: 8755604 DOI: 10.1073/pnas.93.15.8068]

31 **Rossner S**. Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease. *Int J Dev Neurosci* 1997; **15**: 835-850 [PMID: 9568532 DOI: 10.1016/S0736-5748(97)00035-X]

32 **Medeiros R**, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, Fisher A, LaFerla FM. Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. *Am J Pathol* 2011; **179**: 980-991 [PMID: 21704011 DOI: 10.1016/j.ajpath.2011.04.041]

33 **Rossner S**, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. *Prog Neurobiol* 1998; **56**: 541-569 [PMID: 9775403 DOI: 10.1016/S0301-0082(98)00044-6]

34 **Inestrosa NC**, Godoy JA, Vargas JY, Arrazola MS, Rios JA, Carvajal FJ, Serrano FG, Farias GG. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation. *Neuromolecular Med* 2013; **15**: 549-569 [PMID: 23842742 DOI: 10.1007/s12017-013-8242-1]

35 **Oz M**, Lorke DE, Yang KH, Petroianu G. On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer's Disease. *Curr Alzheimer Res* 2013; **10**: 618-630 [PMID: 23627750 DOI: 10.2174/15672050113109990132]

36 **Mesulam M**, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. *Ann Neurol* 2004; **55**: 815-828 [PMID: 15174015 DOI: 10.1002/ana.20100]

37 **Gómez-Ramos A**, Díaz-Hernández M, Rubio A, Díaz-Hernández JI, Miras-Portugal MT, Avila J. Characteristics and consequences of muscarinic receptor activation by tau protein. *Eur Neuropsychopharmacol* 2009; **19**: 708-717 [PMID: 19423301 DOI: 10.1016/j.euroneuro.2009.04.006]

38 **Rubio A**, Pérez M, Avila J. Acetylcholine receptors and tau phosphorylation. *Curr Mol Med* 2006; **6**: 423-428 [PMID: 16900665 DOI: 10.2174/156652406777435444]

39 **Keltner NL**. Tacrine: a pharmacological approach to Alzheimer's disease. *J Psychosoc Nurs Ment Health Serv* 1994; **32**: 37-39 [PMID: 8196019]

40 **Aisen PS**, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. *Cold Spring Harb Perspect Med* 2012; **2**: a006395 [PMID: 22393531 DOI: 10.1101/cshperspect.a006395]

41 **Schneider T**, Ilott N, Brolese G, Bizarro L, Asherson PJ, Stolerman IP. Prenatal exposure to nicotine impairs performance of the 5-choice serial reaction time task in adult rats. *Neuropsychopharmacology* 2011; **36**: 1114-1125 [PMID: 21289608 DOI: 10.1038/npp.2010.249]

42 **Caulfield MP**, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev* 1998; **50**: 279-290 [PMID: 9647869]

43 **Brown DA**. Muscarinic acetylcholine receptors (mAChRs) in the nervous system: some functions and mechanisms. *J Mol Neurosci* 2010; **41**: 340-346 [PMID: 20446119 DOI: 10.1007/s12031-010-9377-2]

44 **Levey AI**, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. *J Neurosci* 1991; **11**: 3218-3226 [PMID: 1941081]

45 **Anagnostaras SG**, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat Neurosci* 2003; **6**: 51-58 [PMID: 12483218 DOI: 10.1038/nn992]

46 **Aura J**, Sirviö J, Riekkinen P. Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test. *Eur J Pharmacol* 1997; **333**: 129-134 [PMID: 9314025 DOI: 10.1016/S0014-2999(97)01134-5]

47 **Bymaster FP**, Heath I, Hendrix JC, Shannon HE. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. *J Pharmacol Exp Ther* 1993; **267**: 16-24 [PMID: 7901390]

48 **McCool MF**, Patel S, Talati R, Ragozzino ME. Differential involvement of M1-type and M4-type muscarinic cholinergic receptors in the dorsomedial striatum in task switching. *Neurobiol Learn Mem* 2008; **89**: 114-124 [PMID: 17709264 DOI: 10.1016/j.nlm.2007.06.005]

49 **Soares JC**, Fornari RV, Oliveira MG. Role of muscarinic M1 receptors in inhibitory avoidance and contextual fear conditioning. *Neurobiol Learn Mem* 2006; **86**: 188-196 [PMID: 16647280 DOI: 10.1016/j.nlm.2006.02.006]

50 **Klinkenberg I**, Blokland A. A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment. *Psychopharmacology (Berl)* 2011; **215**: 549-566 [PMID: 21336581 DOI: 10.1007/s00213-011-2171-1]

51 **Robinson AM**, Mangini DF, Burk JA. Task demands dissociate the effects of muscarinic M1 receptor blockade and protein kinase C inhibition on attentional performance in rats. *J Psychopharmacol* 2012; **26**: 1143-1150 [PMID: 21890584 DOI: 10.1177/0269881111415732]

52 **Parasuraman R,** Warm JS, Dember WN. Vigilance: Taxonomy and utility. In: Mark LS, Warm JS, Huston LR, eds. Ergonomics and human factors. New York: Springer; 1987: 11-32

53 **Burk JA**, Lowder MW, Altemose KE. Attentional demands for demonstrating deficits following intrabasalis infusions of 192 IgG-saporin. *Behav Brain Res* 2008; **195**: 231-238 [PMID: 18840475 DOI: 10.1016/j.bbr.2008.09.006]

54 **Gulledge AT**, Bucci DJ, Zhang SS, Matsui M, Yeh HH. M1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons. *J Neurosci* 2009; **29**: 9888-9902 [PMID: 19657040 DOI: 10.1523/JNEUROSCI.1366-09.2009]

55 **Zhang Y**, Hamilton SE, Nathanson NM, Yan J. Decreased input-specific plasticity of the auditory cortex in mice lacking M1 muscarinic acetylcholine receptors. *Cereb Cortex* 2006; **16**: 1258-1265 [PMID: 16292003 DOI: 10.1093/cercor/bhj067]

56 **Packard MG**, Regenold W, Quirion R, White NM. Post-training injection of the acetylcholine M2 receptor antagonist AF-DX 116 improves memory. *Brain Res* 1990; **524**: 72-76 [PMID: 2400933 DOI: 10.1016/0006-8993(90)90493-U]

57 **Quirion R**, Wilson A, Rowe W, Aubert I, Richard J, Doods H, Parent A, White N, Meaney MJ. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. *J Neurosci* 1995; **15**: 1455-1462 [PMID: 7869110]

58 **Carey GJ**, Billard W, Binch H, Cohen-Williams M, Crosby G, Grzelak M, Guzik H, Kozlowski JA, Lowe DB, Pond AJ, Tedesco RP, Watkins RW, Coffin VL. SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. *Eur J Pharmacol* 2001; **431**: 189-200 [PMID: 11728425 DOI: 10.1016/S0014-2999(01)01440-6]

59 **Calabresi P**, Centonze D, Gubellini P, Pisani A, Bernardi G. Blockade of M2-like muscarinic receptors enhances long-term potentiation at corticostriatal synapses. *Eur J Neurosci* 1998; **10**: 3020-3023 [PMID: 9758172 DOI: 10.1111/j.1460-9568.1998.00348.x]

60 **Poulin B**, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC, Bottrill A, Mistry S, Wess J, Rosethorne EM, Charlton SJ, Tobin AB. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. *Proc Natl Acad Sci U S A* 2010; **107**: 9440-9445 [PMID: 20439723 DOI: 10.1073/pnas.0914801107]

61 **Barrantes GE**, Murphy CT, Westwick J, Wonnacott S. Nicotine increases intracellular calcium in rat hippocampal neurons via voltage-gated calcium channels. *Neurosci Lett* 1995; **196**: 101-104 [PMID: 7501232 DOI: 10.1016/0304-3940(95)11859-U]

62 **Berg DK**, Conroy WG. Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. *J Neurobiol* 2002; **53**: 512-523 [PMID: 12436416 DOI: 10.1002/neu.10116]

63 **Berg DK**, Conroy WG, Liu Z, Zago WM. Nicotinic signal transduction machinery. *J Mol Neurosci* 2006; **30**: 149-152 [PMID: 17192663 DOI: 10.1385/JMN: 30: 1: 149]

64 **Fenster CP**, Rains MF, Noerager B, Quick MW, Lester RA. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. *J Neurosci* 1997; **17**: 5747-5759 [PMID: 9221773]

65 **Nashmi R**, Lester HA. CNS localization of neuronal nicotinic receptors. *J Mol Neurosci* 2006; **30**: 181-184 [PMID: 17192671 DOI: 10.1385/JMN: 30: 1: 181]

66 **Wonnacott S**, Barik J, Dickinson J, Jones IW. Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. *J Mol Neurosci* 2006; **30**: 137-140 [PMID: 17192660 DOI: 10.1385/JMN: 30: 1: 137]

67 **Counotte DS**, Goriounova NA, Li KW, Loos M, van der Schors RC, Schetters D, Schoffelmeer AN, Smit AB, Mansvelder HD, Pattij T, Spijker S. Lasting synaptic changes underlie attention deficits caused by nicotine exposure during adolescence. *Nat Neurosci* 2011; **14**: 417-419 [PMID: 21336271 DOI: 10.1038/nn.2770]

68 **Counotte DS**, Spijker S, Van de Burgwal LH, Hogenboom F, Schoffelmeer AN, De Vries TJ, Smit AB, Pattij T. Long-lasting cognitive deficits resulting from adolescent nicotine exposure in rats. *Neuropsychopharmacology* 2009; **34**: 299-306 [PMID: 18580873 DOI: 10.1038/npp.2008.96]

69 **Smith LN**, McDonald CG, Bergstrom HC, Brielmaier JM, Eppolito AK, Wheeler TL, Falco AM, Smith RF. Long-term changes in fear conditioning and anxiety-like behavior following nicotine exposure in adult versus adolescent rats. *Pharmacol Biochem Behav* 2006; **85**: 91-97 [PMID: 16919320 DOI: 10.1016/j.pbb.2006.07.014]

70 **Spaeth AM**, Barnet RC, Hunt PS, Burk JA. Adolescent nicotine exposure disrupts context conditioning in adulthood in rats. *Pharmacol Biochem Behav* 2010; **96**: 501-506 [PMID: 20655941 DOI: 10.1016/j.pbb.2010.07.011]

71 **Mirza NR**, Bright JL. Nicotine-induced enhancements in the five-choice serial reaction time task in rats are strain-dependent. *Psychopharmacology (Berl)* 2001; **154**: 8-12 [PMID: 11292010 DOI: 10.1007/s002130000605]

72 **Mirza NR**, Stolerman IP. Nicotine enhances sustained attention in the rat under specific task conditions. *Psychopharmacology (Berl)* 1998; **138**: 266-274 [PMID: 9725748 DOI: 10.1007/s002130050671]

73 **McQuail JA**, Burk JA. Evaluation of muscarinic and nicotinic receptor antagonists on attention and working memory. *Pharmacol Biochem Behav* 2006; **85**: 796-803 [PMID: 17196638 DOI: 10.1016/j.pbb.2006.11.015]

74 **Turchi J**, Holley LA, Sarter M. Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. *Psychopharmacology (Berl)* 1995; **118**: 195-205 [PMID: 7617808 DOI: 10.1007/BF02245840]

75 **Hahn B**, Stolerman IP. Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine. *Neuropsychopharmacology* 2002; **27**: 712-722 [PMID: 12431846 DOI: 10.1016/S0893-133X(02)00348-2]

76 **Mancuso G**, Andres P, Ansseau M, Tirelli E. Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study. *Psychopharmacology (Berl)* 1999; **142**: 18-23 [PMID: 10102778 DOI: 10.1007/s002130050857]

77 **Howe WM**, Ji J, Parikh V, Williams S, Mocaër E, Trocmé-Thibierge C, Sarter M. Enhancement of attentional performance by selective stimulation of alpha4beta2(\*) nAChRs: underlying cholinergic mechanisms. *Neuropsychopharmacology* 2010; **35**: 1391-1401 [PMID: 20147893 DOI: 10.1038/npp.2010.9]

78 **Rezvani AH**, Cauley M, Xiao Y, Kellar KJ, Levin ED. Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats. *Psychopharmacology (Berl)* 2013; **226**: 35-43 [PMID: 23100170 DOI: 10.1007/s00213-012-2895-6]

79 **Rezvani AH**, Cauley M, Sexton H, Xiao Y, Brown ML, Paige MA, McDowell BE, Kellar KJ, Levin ED. Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. *Psychopharmacology (Berl)* 2011; **215**: 621-630 [PMID: 21274704 DOI: 10.1007/s00213-010-2161-8]

80 **Leiser SC**, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. *Pharmacol Ther* 2009; **122**: 302-311 [PMID: 19351547 DOI: 10.1016/j.pharmthera.2009.03.009]

81 **Young JW**, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, Finlayson K, Sharkey J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. *Eur Neuropsychopharmacol* 2007; **17**: 145-155 [PMID: 16650968 DOI: 10.1016/j.euroneuro.2006.03.008]

82 **Cilia J**, Cluderay JE, Robbins MJ, Reavill C, Southam E, Kew JN, Jones DN. Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist. *Psychopharmacology (Berl)* 2005; **182**: 214-219 [PMID: 16001118 DOI: 10.1007/s00213-005-0069-5]

83 **Suemaru K**, Yasuda K, Umeda K, Araki H, Shibata K, Choshi T, Hibino S, Gomita Y. Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors. *Br J Pharmacol* 2004; **142**: 843-850 [PMID: 15197106 DOI: 10.1038/sj.bjp.0705855]

84 **Grottick AJ**, Haman M, Wyler R, Higgins GA. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. *Neuropsychopharmacology* 2003; **28**: 880-887 [PMID: 12637951]

85 **Leblond L**, Beaufort C, Delerue F, Durkin TP. Differential roles for nicotinic and muscarinic cholinergic receptors in sustained visuo-spatial attention? A study using a 5-arm maze protocol in mice. *Behav Brain Res* 2002; **128**: 91-102 [PMID: 11755693 DOI: 10.1016/S0166-4328(01)00306-0]

86 **Mirza NR**, Stolerman IP. The role of nicotinic and muscarinic acetylcholine receptors in attention. *Psychopharmacology (Berl)* 2000; **148**: 243-250 [PMID: 10755737 DOI: 10.1007/s002130050048]

87 **Levin ED**, Bushnell PJ, Rezvani AH. Attention-modulating effects of cognitive enhancers. *Pharmacol Biochem Behav* 2011; **99**: 146-154 [PMID: 21334367 DOI: 10.1016/j.pbb.2011.02.008]

88 **Masuoka T**, Kamei C. The role of nicotinic receptors in the amelioration of cholinesterase inhibitors in scopolamine-induced memory deficits. *Psychopharmacology (Berl)* 2009; **206**: 259-265 [PMID: 19639304 DOI: 10.1007/s00213-009-1603-7]

89 **Yamasaki M**, Matsui M, Watanabe M. Preferential localization of muscarinic M1 receptor on dendritic shaft and spine of cortical pyramidal cells and its anatomical evidence for volume transmission. *J Neurosci* 2010; **30**: 4408-4418 [PMID: 20335477 DOI: 10.1523/JNEUROSCI.5719-09.2010]

90 **Sarter M**, Parikh V, Howe WM. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. *Nat Rev Neurosci* 2009; **10**: 383-390 [PMID: 19377503 DOI: 10.1038/nrn2635]

91 **Conn PJ**, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. *Trends Pharmacol Sci* 2009; **30**: 148-155 [PMID: 19201489 DOI: 10.1016/j.tips.2008.12.002]

92 **Pandya A**, Yakel JL. Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors. *Biochem Pharmacol* 2011; **82**: 952-958 [PMID: 21596025 DOI: 10.1016/j.bcp.2011.04.020]

93 **Pandya AA**, Yakel JL. Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies. *Biochem Pharmacol* 2013; In press [PMID: 23732296 DOI: 10.1016/j.bcp.2013.05.018]

94 **Prickaerts J**, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. *Neuropharmacology* 2012; **62**: 1099-1110 [PMID: 22085888 DOI: 10.1016/j.neuropharm.2011.10.024]

95 **Tarr JC**, Turlington ML, Reid PR, Utley TJ, Sheffler DJ, Cho HP, Klar R, Pancani T, Klein MT, Bridges TM, Morrison RD, Blobaum AL, Xiang Z, Daniels JS, Niswender CM, Conn PJ, Wood MR, Lindsley CW. Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. *ACS Chem Neurosci* 2012; **3**: 884-895 [PMID: 23173069 DOI: 10.1021/cn300068s]

96 **Paine TA**, Neve RL, Carlezon WA. Attention deficits and hyperactivity following inhibition of cAMP-dependent protein kinase within the medial prefrontal cortex of rats. *Neuropsychopharmacology* 2009; **34**: 2143-2155 [PMID: 19387423 DOI: 10.1038/npp.2009.40]

97 **Battaini F**, Pascale A, Lucchi L, Pasinetti GM, Govoni S. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. *Exp Neurol* 1999; **159**: 559-564 [PMID: 10506528 DOI: 10.1006/exnr.1999.7151]

98 **Masliah E**, Cole GM, Hansen LA, Mallory M, Albright T, Terry RD, Saitoh T. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. *J Neurosci* 1991; **11**: 2759-2767 [PMID: 1880547]

99 **Wang HY**, Pisano MR, Friedman E. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. *Neurobiol Aging* 1994; **15**: 293-298 [PMID: 7936052 DOI: 10.1016/0197-4580(94)90023-X]

101 **Tsang SW**, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, Wong PT, Lai MK. Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. *Neurobiol Aging* 2007; **28**: 1381-1387 [PMID: 16828202 DOI: 10.1016/j.neurobiolaging.2006.06.001]

101 **Sun MK**, Alkon DL. Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. *Pharmacol Ther* 2010; **127**: 66-77 [PMID: 20382181 DOI: 10.1016/j.pharmthera.2010.03.001]

102 **Wender PA**, Hinkle KW, Koehler MF, Lippa B. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. *Med Res Rev* 1999; **19**: 388-407 [PMID: 10502742 DOI: 10.1002/(SICI)1098-1128(199909)19: 5<388: : AID-MED6>3.0.CO; 2-H]

**P-Reviewers** Blokland A, Nistico R, Perry G

**S-Editor** Zhai HH **L-Editor E-Editor**